Bausch Health Companies (TSX:BHC) - Hisse Senedi Fiyatı, Haberler ve Analizler

BHC Stoklara Genel Bakış

Bausch Health Companies Inc. Amerika Birleşik Devletleri'nde ve uluslararası alanda çeşitlendirilmiş bir özel ilaç ve tıbbi cihaz şirketi olarak faaliyet göstermektedir. Daha fazla detay

BHC temel anali̇z
Kar Tanesi Skoru
Değerleme	5/6
Gelecekteki Büyüme	3/6
Geçmiş Performans	0/6
Finansal Sağlık	2/6
Temettüler	0/6

Ödüller

Adil değer tahminimizden 83.7% daha düşük bir oranda işlem görüyor

Kazançların yılda 218.28% oranında artması öngörülüyor

Kazançlar son 5 yılda yılda 34.6% oranında arttı

Rakiplerine ve sektöre kıyasla iyi değerde işlem görüyor

Risk Analizi

Negatif hissedar öz sermayesi

Bausch Health Companies Inc. Rakipler

Green Thumb Industries

CNSX:GTII

CA$3.1b

Curaleaf Holdings

TSX:CURA

CA$2.1b

Trulieve Cannabis

CNSX:TRUL

CA$1.6b

Cronos Group

TSX:CRON

CA$1.1b

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Bausch Health Companies
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$11.39
52 Haftanın En Yüksek Seviyesi	US$15.43
52 Haftanın En Düşük Seviyesi	US$5.45
Beta	0.74
11 Aylık Değişim	0%
3 Aylık Değişim	44.36%
1 Yıllık Değişim	18.77%
33 Yıllık Değişim	-61.38%
5 Yıllık Değişim	-69.90%
Halka arzdan bu yana değişim	1,785.23%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	BHC	CA Pharmaceuticals	CA Pazar
7D	-0.8%	0.03%	1.3%
1Y	18.8%	-20.8%	23.7%

Getiri vs. Endüstri: BHC geçen yıl % -20.8 oranında getiri sağlayan Canadian Pharmaceuticals sektörünü aştı.

Getiri vs Piyasa: BHC geçen yıl % 23.7 oranında getiri sağlayan Canadian Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is BHC's price volatile compared to industry and market?
BHC volatility
BHC Average Weekly Movement	7.1%
Pharmaceuticals Industry Average Movement	11.6%
Market Average Movement	8.4%
10% most volatile stocks in CA Market	17.5%
10% least volatile stocks in CA Market	3.0%

İstikrarlı Hisse Senedi Fiyatı: BHC son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: BHC 'nin haftalık oynaklığı ( 7% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
n/a	20,270	Tom Appio	www.bauschhealth.com

Bausch Health Companies Inc. Amerika Birleşik Devletleri'nde ve uluslararası alanda çeşitlendirilmiş bir özel ilaç ve tıbbi cihaz şirketi olarak faaliyet göstermektedir. Başta gastroenteroloji, hepatoloji, nöroloji, dermatoloji, uluslararası ilaçlar, reçetesiz (OTC) ürünler, estetik tıbbi cihazlar ve göz sağlığı alanlarında bir dizi ürün geliştirmekte, üretmekte ve pazarlamaktadır. Şirket beş segmentte faaliyet göstermektedir: Salix, International, Solta Medical, Diversified ve Bausch + Lomb.

Bausch Health Companies Inc. Temel Bilgiler Özeti

Bausch Health Companies'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
BHC temel i̇stati̇sti̇kler
Piyasa değeri	CA$4.07b
Kazançlar(TTM)	-CA$249.64m
Gelir(TTM)	CA$13.29b

0.3x

P/S Oranı

-16.8x

F/K Oranı

BHC aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
BHC gelir tablosu (TTM)
Gelir	US$9.47b
Gelir Maliyeti	US$2.76b
Brüt Kâr	US$6.71b
Diğer Giderler	US$6.89b
Kazançlar	-US$178.00m

Son Raporlanan Kazançlar

Sep 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-0.48
Brüt Marj	70.87%
Net Kâr Marjı	-1.88%
Borç/Özkaynak Oranı	-8,887.2%

BHC uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

BHC Stoklara Genel Bakış

Ödüller

Risk Analizi

Bausch Health Companies Inc. Rakipler

CNSX:GTII

CA$3.1b

TSX:CURA

CA$2.1b

CNSX:TRUL

CA$1.6b

TSX:CRON

CA$1.1b

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Bausch Health Companies Inc. Receives Positive Reimbursement Recommendations for Cabtreo in Canada

Forecast breakeven date pushed back to 2025

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Bausch Health Companies Inc. and Salix Pharmaceuticals Announce Results of an Analysis of Xifaxan (rifaximin) Monotherapy Will Be Presented During A Presidential Plenary Session of the American College of Gastroenterology 2024 Annual Scientific Meeting Taking Place October 25-30 in Philadelphia, PA

Bausch Health Companies Inc. to Report Q3, 2024 Results on Oct 30, 2024

Health Canada Approves the Bausch Health's (Pr)CABTREO Topical Gel

Recent updates

Bausch Health Companies Inc. Receives Positive Reimbursement Recommendations for Cabtreo in Canada

Forecast breakeven date pushed back to 2025

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Bausch Health Companies Inc. and Salix Pharmaceuticals Announce Results of an Analysis of Xifaxan (rifaximin) Monotherapy Will Be Presented During A Presidential Plenary Session of the American College of Gastroenterology 2024 Annual Scientific Meeting Taking Place October 25-30 in Philadelphia, PA

Bausch Health Companies Inc. to Report Q3, 2024 Results on Oct 30, 2024

Health Canada Approves the Bausch Health's (Pr)CABTREO Topical Gel

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Bausch Health Companies Inc. Raises Earnings Guidance for the Full Year 2024

Bausch Health Companies Inc. Announces Appointment of Aimee Lenar as Executive Vice President, US Pharma

Bausch Health Companies Inc. to Report Q2, 2024 Results on Aug 01, 2024

Bausch Health Companies Inc. and Salix Pharmaceuticals to Present Late-Breaking Data from Phase 2 Trial of Amiselimod in Active Ulcerative Colitis at Digestive Disease Week 2024

Bausch Health Companies Inc. Approves Directorate Appointments

First quarter 2024 earnings: EPS misses analyst expectations

Bausch Health, Canada Inc. Announces Acne Vulgaris Treatment PrARAZLO(TM) (Tazarotene Lotion, 0.045%) Now Available to Patients Through British Columbia PharmaCare Public Drug Plan

Bausch Health Companies Inc. to Report Q1, 2024 Results on May 02, 2024

Bausch Health, Canada Inc. Announces First Public Drug Plan Listings for (Pr)UCERIS(R) (budesonide) Aerosol Foam to Help Address the Unmet Need for the Treatment of Mild to Moderate Distal Ulcerative Colitis in Adults

Insufficient new directors

Bausch Health Companies Inc. and Salix Pharmaceuticals Announces Phase 2 Investigator-Initiated Study of RELISTOR in Patients with Resectable Head and Neck Squamous Cell Carcinoma

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Bausch Health Companies Inc., Annual General Meeting, May 14, 2024

Bausch Health Companies Inc. to Report Q4, 2023 Results on Feb 22, 2024

Bausch Health Companies Inc. Announces the U.S. Launch of CABTREO Topical Gel

Bausch Health Companies Inc. and Salix Pharmaceuticals Ltd. Provides Update on Court of Appeals for the Federal Circuit Hears Oral Arguments on Patent Dispute

Bausch Health Companies Inc. Announces Positive Topline Results from Global Phase 2 Study Evaluating Amiselimod (An S1p Antagonist) to Treat Ulcerative Colitis

Bausch Health, Canada Announces DUOBRII Lotion to Treat Moderate to Severe Plaque Psoriasis Now Available Through Quebec's Public Drug Plan

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

FDA Approves Bausch Health Companies Inc. and Its Dermatology Business, Ortho Dermatologics's Cabtreo Topical Gel for the Treatment of Acne Vulgaris in Patients Twelve Years of Age and Older

Bausch Health Companies Inc. to Report Q3, 2023 Results on Nov 02, 2023

Bausch Health Companies Inc. Announces Executive Changes

Bausch Health Companies Inc. Announces New Treatment PrUCERIS (Budesonide) Aerosol Foam Now Available Across Canada to Treat Mild to Moderate Distal Ulcerative Colitis in Adults

Bernstein Liebhard LLP Files A Securities Class Action Lawsuit Against Bausch Health Companies Inc

Bernstein Liebhard LLP Files A Securities Class Action Lawsuit Against Bausch Health Companies Inc

Bausch Health Companies Inc. Raises Earnings Guidance for the Fiscal Year 2023

Second quarter 2023 earnings released: EPS: US$0.072 (vs US$0.40 loss in 2Q 2022)

Levi & Korsinsky, LLP Files Complaint to Recover Losses Suffered by Purchasers of Bausch Health Companies Inc

Bausch Health Companies Inc. to Report Q2, 2023 Results on Aug 03, 2023

New major risk - Financial position

Forecast to breakeven in 2025

First quarter 2023 earnings: EPS misses analyst expectations

Bausch Health Companies Inc. Provides Consolidated Earnings Guidance for the Full Year 2023

Forecast breakeven date pushed back to 2025

Full year 2022 earnings: EPS misses analyst expectations

Investor sentiment improves as stock rises 23%

Bausch Health Companies Inc. to Report Q4, 2022 Results on Feb 23, 2023

Investor sentiment improved over the past week

Bausch Health Companies Inc. Announces Availability of ARAZLOTM

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2022 earnings: EPS exceeds analyst expectations

Bausch Health Companies Inc. Revises Consolidated Earnings Guidance for the Full Year 2022

Bausch Health Companies Inc. to Report Q3, 2022 Results on Nov 03, 2022

Bausch Health Companies Inc. and Glenmark Specialty S.A. Announce the Approval of RYALTRIS® in Canada

Insider recently sold CA$932k worth of stock

Bausch Health Companies Inc.(TSX:BHC) dropped from FTSE All-World Index (USD)

Bausch Health Companies Inc. Responds to Norwich Pharmaceuticals Tentative FDA Approval for 200 mg Rifaximin

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Bausch Health Companies Inc. to Appeal XIFAXAN® Patent Decision to U.S. Court of Appeals for the Federal Circuit

Second quarter 2022 earnings: EPS and revenues miss analyst expectations